X Curso internacional de avances en Oncología

Investigación y nuevos fármacos

Translated title of the contribution: 10th International course in progress in Oncology: Research and new drugs

Enrique Espinosa Arranz, Manuel Hidalgo, Juan Carlos Lacal Sanjuán, Félix Reyes, M. Luisa García De Paredes, César Picó, Rosario Perona Abellón, K. Polyak

Research output: Contribution to journalArticle

Abstract

This international symposium was hold in Cádiz in November 2002. In the first conference, a classification of anticancer drugs including all the new compounds was proposed. The role of cholino-kinase in oncogenesis was revised, as well as the possibility to use this model in the development of new drugs. The first group of conferences was finished with a speech about how we are investigating with new drugs, considering the limitations of our traditional paradigm. The second group of conferences included a revision of different drugs: monoclonal antibodies, gefitinib, imatinib and Cox-2 inhibitors. The speakers commented on the results of clinical trials and the future investigation with these drugs. Finally, the third block included a revision a techniques in molecular oncology and a speech about the kind of information that we are achieving through the use of these techniques.

Original languageSpanish
Pages (from-to)98-110
Number of pages13
JournalClinical and Translational Oncology
Volume5
Issue number2
StatePublished - Mar 2003

Fingerprint

Research
Pharmaceutical Preparations
Carcinogenesis
Phosphotransferases
Monoclonal Antibodies
Clinical Trials
gefitinib
Imatinib Mesylate

Keywords

  • Cholino-kinase
  • Gefitinib
  • Monoclonal imatinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Arranz, E. E., Hidalgo, M., Sanjuán, J. C. L., Reyes, F., De Paredes, M. L. G., Picó, C., ... Polyak, K. (2003). X Curso internacional de avances en Oncología: Investigación y nuevos fármacos. Clinical and Translational Oncology, 5(2), 98-110.

X Curso internacional de avances en Oncología : Investigación y nuevos fármacos. / Arranz, Enrique Espinosa; Hidalgo, Manuel; Sanjuán, Juan Carlos Lacal; Reyes, Félix; De Paredes, M. Luisa García; Picó, César; Abellón, Rosario Perona; Polyak, K.

In: Clinical and Translational Oncology, Vol. 5, No. 2, 03.2003, p. 98-110.

Research output: Contribution to journalArticle

Arranz, EE, Hidalgo, M, Sanjuán, JCL, Reyes, F, De Paredes, MLG, Picó, C, Abellón, RP & Polyak, K 2003, 'X Curso internacional de avances en Oncología: Investigación y nuevos fármacos', Clinical and Translational Oncology, vol. 5, no. 2, pp. 98-110.
Arranz EE, Hidalgo M, Sanjuán JCL, Reyes F, De Paredes MLG, Picó C et al. X Curso internacional de avances en Oncología: Investigación y nuevos fármacos. Clinical and Translational Oncology. 2003 Mar;5(2):98-110.
Arranz, Enrique Espinosa ; Hidalgo, Manuel ; Sanjuán, Juan Carlos Lacal ; Reyes, Félix ; De Paredes, M. Luisa García ; Picó, César ; Abellón, Rosario Perona ; Polyak, K. / X Curso internacional de avances en Oncología : Investigación y nuevos fármacos. In: Clinical and Translational Oncology. 2003 ; Vol. 5, No. 2. pp. 98-110.
@article{0d18d5288b384274bc8bbd5b9402b5a1,
title = "X Curso internacional de avances en Oncolog{\'i}a: Investigaci{\'o}n y nuevos f{\'a}rmacos",
abstract = "This international symposium was hold in C{\'a}diz in November 2002. In the first conference, a classification of anticancer drugs including all the new compounds was proposed. The role of cholino-kinase in oncogenesis was revised, as well as the possibility to use this model in the development of new drugs. The first group of conferences was finished with a speech about how we are investigating with new drugs, considering the limitations of our traditional paradigm. The second group of conferences included a revision of different drugs: monoclonal antibodies, gefitinib, imatinib and Cox-2 inhibitors. The speakers commented on the results of clinical trials and the future investigation with these drugs. Finally, the third block included a revision a techniques in molecular oncology and a speech about the kind of information that we are achieving through the use of these techniques.",
keywords = "Cholino-kinase, Gefitinib, Monoclonal imatinib",
author = "Arranz, {Enrique Espinosa} and Manuel Hidalgo and Sanju{\'a}n, {Juan Carlos Lacal} and F{\'e}lix Reyes and {De Paredes}, {M. Luisa Garc{\'i}a} and C{\'e}sar Pic{\'o} and Abell{\'o}n, {Rosario Perona} and K. Polyak",
year = "2003",
month = "3",
language = "Spanish",
volume = "5",
pages = "98--110",
journal = "Clinical and Translational Oncology",
issn = "1699-048X",
publisher = "Springer-Verlag Italia",
number = "2",

}

TY - JOUR

T1 - X Curso internacional de avances en Oncología

T2 - Investigación y nuevos fármacos

AU - Arranz, Enrique Espinosa

AU - Hidalgo, Manuel

AU - Sanjuán, Juan Carlos Lacal

AU - Reyes, Félix

AU - De Paredes, M. Luisa García

AU - Picó, César

AU - Abellón, Rosario Perona

AU - Polyak, K.

PY - 2003/3

Y1 - 2003/3

N2 - This international symposium was hold in Cádiz in November 2002. In the first conference, a classification of anticancer drugs including all the new compounds was proposed. The role of cholino-kinase in oncogenesis was revised, as well as the possibility to use this model in the development of new drugs. The first group of conferences was finished with a speech about how we are investigating with new drugs, considering the limitations of our traditional paradigm. The second group of conferences included a revision of different drugs: monoclonal antibodies, gefitinib, imatinib and Cox-2 inhibitors. The speakers commented on the results of clinical trials and the future investigation with these drugs. Finally, the third block included a revision a techniques in molecular oncology and a speech about the kind of information that we are achieving through the use of these techniques.

AB - This international symposium was hold in Cádiz in November 2002. In the first conference, a classification of anticancer drugs including all the new compounds was proposed. The role of cholino-kinase in oncogenesis was revised, as well as the possibility to use this model in the development of new drugs. The first group of conferences was finished with a speech about how we are investigating with new drugs, considering the limitations of our traditional paradigm. The second group of conferences included a revision of different drugs: monoclonal antibodies, gefitinib, imatinib and Cox-2 inhibitors. The speakers commented on the results of clinical trials and the future investigation with these drugs. Finally, the third block included a revision a techniques in molecular oncology and a speech about the kind of information that we are achieving through the use of these techniques.

KW - Cholino-kinase

KW - Gefitinib

KW - Monoclonal imatinib

UR - http://www.scopus.com/inward/record.url?scp=84873451934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873451934&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 98

EP - 110

JO - Clinical and Translational Oncology

JF - Clinical and Translational Oncology

SN - 1699-048X

IS - 2

ER -